Genitourinary Cancers | Specialty

The genitourinary cancers condition center is a comprehensive resource for clinical news and expert insights on genitourinary cancers. Read more at OncLive.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Dr Singer on Choosing Between Frontline IO/IO and IO/TKI Regimens in RCC

January 23rd 2025

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

Dr McGregor on Future Biomarker Analyses With Nivolumab Plus Ipilimumab in Bladder Cancer

January 23rd 2025

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Dr Braun on Future Directions for Research Into Protein Glycosylation in RCC

January 22nd 2025

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48

January 22nd 2025

Felix Y. Feng, MD, a radiation oncologist and researcher at UCSF, died of cancer on December 10, 2024, at 48 years old.

Dr Braun on Protein Glycosylation as a Potential Biomarker of Response in RCC

January 20th 2025

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

Dr McGregor on the Potential Use of Checkpoint Inhibitors in Rare GU Cancers

January 20th 2025

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC

January 16th 2025

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.

Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm

January 16th 2025

Thomas Westbrook, MD, discusses the non–clear cell renal cell carcinoma research that informs his clinical practice.

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers

January 15th 2025

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

January 15th 2025

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations

January 14th 2025

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC

January 11th 2025

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC

January 9th 2025

Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

January 8th 2025

Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology

December 27th 2024

A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s minds of medicine to improve outcomes further.

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

December 13th 2024

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.

NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC

December 3rd 2024

NDI-101150 monotherapy demonstrated antitumor activity and was well tolerated among patients with heavily pretreated renal cell carcinoma.

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

November 27th 2024

ALLO-316, a CD70-directed CAR T-cell therapy, demonstrated preliminary efficacy and safety in CD70-positive ccRCC.